Secukinumab

• Plaque Psoriasis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Axial Spondyloarthritis

Secukinumab is a fully human monoclonal antibody that selectively binds and neutralizes interleukin-17A (IL-17A), a cytokine central to the inflammation of plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Marketed as Cosentyx, it is a subcutaneous biologic given by injection at home or in clinic, with rapid skin clearance often visible within a few weeks. As an immunology and dermatologic therapy, secukinumab is co-managed by primary care and specialty teams, with primary care often handling vaccination, infection screening, and overall preventive care.

Mechanism of Action

IL-17A is a pro-inflammatory cytokine produced primarily by Th17 helper T cells but also by innate lymphoid cells, mast cells, and neutrophils. It binds to a heterodimeric receptor (IL-17RA and IL-17RC) expressed on keratinocytes, synoviocytes, and other epithelial cells, triggering nuclear factor-kappa B and MAP kinase signaling that drives keratinocyte hyperproliferation, recruitment of neutrophils, expression of antimicrobial peptides, and production of additional inflammatory cytokines and chemokines. In psoriatic skin lesions, IL-17A levels are markedly elevated, and IL-17A signaling sits at the heart of the histologic and clinical picture — thickened plaques, scaling, neutrophilic microabscesses, and erythema. In axial spondyloarthritis, IL-17A drives the entheseal and synovial inflammation that produces back pain and structural damage.

Secukinumab binds IL-17A with picomolar affinity and prevents its interaction with the IL-17 receptor, halting downstream signaling. Within weeks, keratinocyte turnover normalizes, neutrophilic infiltrate clears, and the plaques resolve. Skin response is typically measurable by week 4 and substantial by week 12, with a high proportion of patients achieving 90 to 100 percent improvement in Psoriasis Area and Severity Index scores. Importantly, secukinumab spares IL-17F and IL-17C, which contributes to the favorable safety profile relative to broader immunosuppressants. Detailed prescribing information is available from the FDA, and the American Academy of Dermatology publishes psoriasis treatment guidelines.

Clinical Use

FDA-approved indications include moderate-to-severe plaque psoriasis in adults and children age 6 and older, active psoriatic arthritis, active ankylosing spondylitis, active non-radiographic axial spondyloarthritis with objective signs of inflammation, and active enthesitis-related arthritis in children age 4 and older. Current dermatology guidelines position IL-17 inhibitors among the most effective biologic options for plaque psoriasis, comparable to IL-23 inhibitors such as guselkumab, risankizumab, and tildrakizumab, and frequently superior to TNF inhibitors such as adalimumab, etanercept, and infliximab for skin clearance.

For psoriatic arthritis, the choice between an IL-17 inhibitor, an IL-23 inhibitor, and a TNF inhibitor depends on disease distribution, comorbidities, and patient preference. IL-17 inhibitors are particularly effective for axial disease and enthesitis. They are generally avoided in patients with active or recent inflammatory bowel disease because IL-17 blockade can exacerbate Crohn disease and ulcerative colitis. Alternatives within the IL-17 class include ixekizumab and brodalumab, which targets the IL-17 receptor rather than the cytokine. Secukinumab can be used as monotherapy or with methotrexate. It should not be combined with other biologics or with JAK inhibitors such as tofacitinib and upadacitinib.

How to Take It

Secukinumab is administered as a subcutaneous injection using a prefilled syringe, autoinjector pen (Sensoready), or, less commonly, lyophilized powder reconstituted by a nurse. The standard adult psoriasis induction is 300 mg at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks. For psoriatic arthritis without coexisting psoriasis, the dose is typically 150 mg with the same schedule, with option to escalate to 300 mg. For ankylosing spondylitis the typical maintenance dose is 150 mg every 4 weeks, with possible escalation to 300 mg. Injection sites are rotated between the thighs, abdomen (avoiding the area within 2 inches of the navel), and the back of the upper arms.

Patients refrigerate the medication at 36 to 46°F in the original carton to protect from light, and bring it to room temperature for 15 to 30 minutes before injection to reduce sting. Do not shake. The needle cap of the prefilled syringe contains natural rubber latex, so latex-allergic patients use the autoinjector or have someone else uncap it. A missed dose is given as soon as remembered, then the schedule resumed; if more than one cycle has been missed, the prescribing physician advises whether re-induction is needed. Most patients tolerate the first injection well; mild injection site redness, swelling, or itching is common and usually self-limited. Skin clearance often becomes apparent by week 3 to 4.

Monitoring and Follow-Up

Before initiation, screen for active and latent tuberculosis with an interferon-gamma release assay or tuberculin skin test, hepatitis B and C serologies, baseline CBC, comprehensive metabolic panel, and a careful inflammatory bowel disease history. All age-appropriate vaccinations should be brought up to date before starting; live vaccines (MMR, varicella, yellow fever, intranasal influenza, live zoster) cannot be given during therapy. Recombinant zoster, pneumococcal, hepatitis B, and updated COVID-19 vaccines are appropriate and may be given on therapy.

During treatment, periodic CBC and liver enzymes are reasonable. Patients are asked at each visit about persistent diarrhea, abdominal pain, or rectal bleeding that could signal new or worsening inflammatory bowel disease. Yearly TB screening is appropriate for patients in or returning from endemic areas. Skin examinations and disease-specific assessments — Psoriasis Area and Severity Index for psoriasis, joint counts for psoriatic arthritis, BASDAI for ankylosing spondylitis — guide ongoing therapy decisions. Suboptimal response after 16 weeks may warrant dose escalation or change of agent.

Special Populations

Elderly patients tolerate secukinumab similarly to younger adults with no dose adjustment required, though baseline infection screening is particularly important. Renal and hepatic impairment do not require dose changes; clearance is via reticuloendothelial protein catabolism rather than kidney or liver. Pregnancy data are limited; IgG antibodies cross the placenta in the second and third trimesters, and use during pregnancy is individualized after risk-benefit discussion. Lactation excretion is unknown though minimal absorption is expected. Pediatric approval extends to plaque psoriasis at age 6 and enthesitis-related arthritis at age 4. Patients with active or historical inflammatory bowel disease are generally steered toward TNF or IL-23 inhibitors instead.

When to Contact Your Doctor

Call promptly for fever above 100.4°F, productive cough lasting more than a few days, painful urination, or any sign of serious infection. New or worsening diarrhea, abdominal pain, blood in stool, or unexplained weight loss may indicate inflammatory bowel disease and requires evaluation. A vesicular rash in a band-like distribution suggests shingles. Sudden hives, swelling of the face or throat, wheezing, or difficulty breathing after an injection may represent anaphylaxis and requires emergency care. Persistent injection site reactions that worsen rather than improve over a few days deserve a call. Plan ahead for any live vaccinations, surgical procedures, or pregnancies so therapy can be paused appropriately.

Cost and access are practical realities for biologic therapy. Secukinumab requires prior authorization with most insurers, and manufacturer copay assistance can substantially reduce out-of-pocket cost for commercially insured patients. Patients on long-term IL-17 inhibitor therapy benefit from a deliberate preventive care plan. Annual skin examination by a dermatologist screens for skin cancer and monitors for any unusual rash. Cardiovascular risk reduction — blood pressure control, statin therapy when indicated, smoking cessation, and weight management — addresses the elevated atherosclerotic risk associated with chronic inflammatory disease. Psoriatic arthritis can produce silent radiographic damage; baseline and periodic joint imaging help track disease control objectively. Mental health screening matters because chronic skin and joint disease frequently coexist with anxiety and depression that respond to integrated care. Travel planning should account for the need to refrigerate the medication and to bring documentation of medical necessity through airport security. Patients should report any planned dental or surgical procedures so timing of injections can be coordinated. The combination of biologic therapy with disease-modifying lifestyle interventions delivers the best long-term outcomes.

For a coordinated plan that balances biologic therapy with vaccination, infection screening, and overall preventive care in St. Petersburg, contact us or schedule a visit with our internal medicine team.